Sanjib Dey
Family Medicine · Hauppauge, NYNPI 1609491968
Payments from drug & device makers
Across 137 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$815
- Novo Nordisk$324
- Pfizer$306
- Astellas Pharma US Inc$231
- Neurocrine Biosciences, Inc.$227
- AstraZeneca$205
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,07198%
- Education$692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $815 |
| Novo Nordisk | 15 | $324 |
| Pfizer | 14 | $306 |
| Astellas Pharma US Inc | 7 | $231 |
| Neurocrine Biosciences, Inc. | 5 | $227 |
| AstraZeneca | 6 | $205 |
| Lilly USA, LLC | 10 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $179 |
| Cranial Technologies, Inc | 6 | $142 |
| Lundbeck LLC | 4 | $91 |
| Merck | 4 | $79 |
| Exact Sciences | 3 | $67 |
| Shield Therapeutics Inc | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Boston Scientific | 1 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Travere Therapeutics, Inc. | 1 | $32 |
| GSK | 1 | $20 |
| Abbott | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| Gilead | 1 | $17 |
| Qiagen, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,140 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $42,858 |
| FarxigaDapagliflozin Propanediol | 25 | $40,852 |
| JardianceEmpagliflozin | 19 | $26,130 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $2,009 |
| Oxycodone Hcl | 32 | $1,143 |
| Testosterone Cypionate | 18 | $771 |
| Gabapentin | 33 | $462 |
| Atorvastatin Calcium | 86 | $423 |
| Valsartan | 14 | $408 |
| Levothyroxine Sodium | 35 | $397 |
| Rosuvastatin Calcium | 32 | $395 |
| Metformin Hcl | 70 | $342 |
| Metoprolol Succinate | 18 | $334 |
| Losartan Potassium | 56 | $327 |
| Fluticasone Propionate | 14 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $324 | $42,85827 claims |
| AstraZenecaFarxiga | $205 | $40,85225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Hauppauge
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.